From the desk of The Editor, HealthTechMovers.com
Today we have identified a list of several health stocks that have appear to be trending by receiving buy ratings and showing positive investor sentiment, as well as news headlines. This list includes BioMarin Pharmaceutical (BMRN) which has been recently rated by top Wall Street analysts, most recently by Bank of America Securities.
With that said, our editors here at healthtechmovers.com, are BioMarin Pharmaceutical to our watchlist to see if this momentum continues.
Summary: BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.
- Recent Price: $$75.67
- Yearly Gain: -3.85%
- Market Cap: $14.00B
- P/E Ratio: 424.971
TipRanks.com reports that BioMarin Pharmaceutical currently has 15 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $113.67. The target pricing ranges from a high forecast of $146.00 down to a low forecast of $90.00. BioMarin Pharmaceutical (BMRN)’s last closing price was $$75.67 which would put the average price target at 50.22% upside.
In addition, TradingView issued a Sell rating for BMRN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BMRN.
Other analysts covering BMRN include:
- Unknown Analyst of Credit Suisse issued a Buy rating with the price target of $ 105 on 1 day ago
- Paul Matteis of Stifel Nicolaus issued a Buy rating with the price target of $ 96 on 2 days ago
- Christopher Raymond of Piper Sandler issued a Buy rating with the price target of $ 125 on 2 days ago
- Liana Moussatos of Wedbush issued a Buy rating with the price target of $ 146 on 2 days ago
Here are 3rd party ratings for BMRN:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 41% (104 out of 252)
- News Sentiment: Neutral
- Blogger Consensus: Bullish
- Media Buzz: High
- Insider Signal: Positive
- Investor Sentiment: Negative
- Hedge Fund signal: Negative
The stock market is extremely volatile, and you need to do your own research on BMRN before you decide to make any investment.
Click here for BMRN chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.